Hamburg vows FDA/USP teamwork to fight drug adulteration

Updating public standards to meet new threats brought on by globalization is a top area for FDA and USP collaboration, says FDA commissioner Margaret Hamburg. The distribution of adulterated heparin that proved lethal several years ago is but one reason why. Hamburg describes three collaboration initiatives: joint assessment of physical reference standards, information exchanges on hand-held device applications that screen drugs for adulteration or contamination, and FDA assistance to USP in modernizing monographs to better assess and characterize drug ingredients and products. Release

Sponsored By Digital Pharma Europe

Fierce Pharma Marketing is excited to announce the first virtual Digital Pharma Europe!

This summit will profile best-in-class case studies and senior-level discussions from leaders who are innovating the way we look at the intersection of digital technologies and marketing in Europe.